PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 61 | 1 | 91-97
Article title

The correlation analysis of WWOX expression and cancer related genes in neuroblastoma- a real time RT-PCR study

Content
Title variants
Languages of publication
EN
Abstracts
EN
Neuroblastoma is one of the most common paediatric cancers, described as unpredictable due to diverse patterns of behaviour. WWOX is a tumour suppressor gene whose expression is reduced in many tumour types. Loss of its expression was shown to correlate with more aggressive disease stage and mortality rate. The aim of this study was to investigate the role of the WWOX tumour suppressor gene in neuroblastoma formation. We performed real-time RT-PCR to analyse levels of WWOX expression in 22 neuroblastic tumour samples in correlation with genes involved in cell cycle regulation (CCNE1, CCND1), proliferation (MKI67), apoptosis (BCL2, BIRC5, BAX) and signal transduction (EGFR, ERBB4). We also evaluated two potential mechanisms - promoter methylation (MethylScreen method) and loss of heterozygosity (LOH) status, which could be connected with regulation of WWOX gene expression. We found a positive correlation between WWOX gene and BCL2 and HER4 JM-a and negative with cyclin D1 and E1. Our observations are consistent with previous findings and emphasise the role of WWOX in cell cycle and apoptosis regulation. Moreover, strong positive association with HER4 JM-a in this tumour type may indicate a role for WWOX in neuroblastoma cell differentiation. The presented results indicate that LOH in locus D16S3096 (located in intron 8) may be involved in the regulation of WWOX mRNAexpression. However, no association between methylation status of WWOX promoter and its expression was observed.
Keywords
Year
Volume
61
Issue
1
Pages
91-97
Physical description
Dates
published
2014
accepted
2013-01-20
received
2013-10-10
revised
2013-12-03
(unknown)
2014-01-22
References
  • Abel F, Sjoberg RM, Nilsson S, Kogner P, Martinsson T (2005) Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. Eur J Cancer 41: 635-546.
  • Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H, Croce CM, Elenius K (2007) Association of Wwox with ErbB4 in breast cancer. Cancer Res 67: 9330-9336.
  • Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M, Croce CM ( 2005) WW Domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65: 6764-6772.
  • Aqeilan RI, Hagan JP, Aqeilan HA, Pichiorri F, Fong LY, Croce CM (2007) Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res 67: 5606-5610.
  • Aqeilan RI, Hagan JP, de Bruin A, Rawahneh M, Salah Z, Gaudio E, Siddiqui H, Volinia S, Alder H, Lian JB, Stein GS, Croce CM (2009) Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology 150: 1530-1535.
  • Aqeilan RI, Hassan MQ, de Bruin A, Hagan JP, Volinia S, Palumbo T, Hussain S, Lee SH, Gaur T, Stein GS, Lian JB, Croce CM (2008) The WWOX tumor suppressor is essential for post-natal survival and normal bone metabolism. J Biol Chem 283: 21629-21639.
  • Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, Baffa R, Huebner K, Edmonds P, Croce CM (2004) Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 10: 3053-3058.
  • Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, Hagan JP, Zanesi N, Kaou M, Stein GS, Lian JB, Croce CM (2007) Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104: 3949-3954.
  • Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ, Aldaz CM (2001) WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61: 8068-8073.
  • Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM (2000) WWOX, a Novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60: 2140-2145.
  • Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, Birchmeier C, Riethmacher D (1998) The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous System. Genes Dev 12: 1825-1836.
  • Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87: 8751-8755.
  • Casalini P, Iorio MV, Galmozzi E, Ménard S (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200: 343-350.
  • Chen T, Sahin A, Aldaz CM (1996) Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 56: 5605-5609.
  • Dias EP, Pimenta FJ, Sarquis MS, Dias Filho MA, Aldaz CM, Fujii JB, Gomez RS, De Marco L (2007) Association between decreased wwox protein expression and thyroid cancer development. Thyroid 17: 1055-1059.
  • Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N, Yendamuri S, Han SY, Amadori D, Huebner K, Croce CM (2005) WWOX Gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 102: 15611-1516.
  • Furuta S, Ohira M, Machida T, Hamano S, Nakagawara A (2000) Analysis of Loss of heterozygosity at 16p12-p13 (familial neuroblastoma locus) in 470 neuroblastomas including both sporadic and mass screening tumors. Med Pediatr Oncol 35: 531-533.
  • Gourley C, Paige AJ, Taylor KJ, Ward C, Kuske B, Zhang J, Sun M, Janczar S, Harrison DJ, Muir M, Smyth JF, Gabra H (2009) WWOX Gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res 69: 4835-4842.
  • Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, McCue P, Huebner K (2004) The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100: 1605-1614.
  • Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P (2009) The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol 23: 125-143.
  • Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T (2004) Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 20: 33-38.
  • Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM (2005) Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65: 9868-9875.
  • Holemon H, Korshunova Y, Ordway JM, Bedell JA, Citek RW, Lakey N, Leon J, Finney M, McPherson JD, Jeddeloh JA (2007) Methylscreen: DNA methylation density monitoring using quantitative PCR. Biotechniques 43: 683-693.
  • Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K (2007) Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 13: 268-274.
  • Izycka-Swieszewska E, Wozniak A, Drozynska E, Kot J, Grajkowska W, Klepacka T, Perek D, Koltan S, Bien E, Limon J (2011) Expression and significance of HER family receptors in neuroblastic tumors. Clin Exp Metastasis 28: 271-282.
  • Kaatsch P (2010) Epidemiology of childhood cancer. Cancer Treat Rev 36: 277-285.
  • Kosla K, Pluciennik E, Kurzyk A, Jesionek-Kupnicka D, Kordek R, Potemski P, Bednarek AK (2011) Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J Neurooncol 101: 207-213.
  • Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M, Croce CM (2002) Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 62: 2258-2260.
  • Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, Rattan S, Cesari R, Nolli ML, Williams NN, Mori M, Kanematsu T, Croce CM (2004) The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10: 2459-2465.
  • Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R (1997) Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 57: 1058-1062.
  • Lewandowska U, Zelazowski M, Seta K, Byczewska M, Pluciennik E, Bednarek AK (2009) WWOX, the tumour suppressor gene affected in multiple cancers. J Physiol Pharmacol 60 (Suppl 1): 47-56.
  • Ludes-Meyers JH, Kil H, Parker-Thornburg J, Kusewitt DF, Bedford MT, Aldaz CM (2009) Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One 4: e7775.
  • Ludes-Meyers JH, Kil H, Nunez MI, Conti CJ, Parker-Thornburg J, Bedford MT, Aldaz CM (2007) WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosomes Cancer 46: 1129-1136.
  • Maeda N, Semba S, Nakayama S, Yanagihara K, Yokozaki H (2010) Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations. Virchows Arch 457: 423-443.
  • Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, Huang S, Cui H, Ding HF (2012) Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene 31: 3785-3795.
  • Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17: 2264-2279.
  • Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, Caron HN (2008) Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 68: 2599-2609.
  • Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE, Sahin A, Klein-Szanto AJ, Aldaz CM (2005) Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89: 99-105.
  • Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, Aldaz CM (2005) WWOX Protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 5: 64.
  • Oue T, Fukuzawa M, Kusafuka T, Kohmoto Y, Imura K, Nagahara S, Okada A (1996) In Situ Detection of DNA fragmentation and expression of Bcl-2 in human neuroblastoma: relation to apoptosis and spontaneous regression. J Pediatr Surg 31: 251-257.
  • Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC, Smyth JF, Porteous DJ, Watson JE (2000) A 700-Kb Physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 60: 1690-1697.
  • Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
  • Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK (2006) WWOX - the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol 32: 153-157.
  • Pluciennik E, Nowakowska M, Wujcicka WI, Sitkiewicz A, Kazanowska B, Zielińska E, Bednarek AK (2012) Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis. Oncol Rep 28: 1417-1422.
  • Qin H R, Iliopoulos D, Semba S (2006) A role for the WWOX gene in prostate cancer. Cancer Res 66: 6477-6481.
  • Ramani P, Lu QL (1994) Expression of Bcl-2 gene product in neuroblastoma. J Pathol 172: 273-278.
  • Ramos D, Abba M, Lopez-Guerrero JA, Rubio J, Solsona E, Almenar S, Llombart-Bosch A, Aldaz CM (2008) Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology 52: 831-839.
  • Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DP (2010) Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer 116: 3233-3243.
  • Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4: 472-480.
  • Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP (1999) The international neuroblastoma pathology classification (the Shimada system). Cancer 86: 364-372.
  • Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P, Dębiec-Rychter M (2000) 16q Heterozygosity loss in Wilms' tumour in children and its clinical importance. Eur J Surg Oncol 26: 61-66.
  • Weiss MJ, Guo C, Shusterman S, Hii G, Mirensky TL, White PS, Hogarty MD, Rebbeck TR, Teare D, Urbanek M, Brodeur GM, Maris JM (2000) Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol 35: 526-530.
  • Xiong Z, Hu S, Wang Z (2010) Cloning of WWOX gene and its growth-inhibiting effects on ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci 30: 365-369.
  • Yendamuri S, Kuroki T, Trapasso F, Henry AC, Dumon KR, Huebner K, Williams NN, Kaiser LR, Croce CM (2003) WW Domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 63: 878-881.
  • Zelazowski MJ, Pluciennik E, Pasz-Walczak G, Potemski P, Kordek R, Bednarek AK (2011) WWOX Expression in colorectal cancer - a real-time quantitative RT-PCR study. Tumour Biol 32: 551-560.
  • Zhou YL, Li YC, Shou F, Liu CQ, Pu Y, Tang H (2010) Reversing effect of exogenous WWOX gene expression on malignant phenotype of primary cultured lung carcinoma cells. Chin Med J (Engl) 123: 615-620.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv61p91kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.